subcutaneous PB1046: Phase IIa started

PhaseBio began a double-blind, placebo-controlled, dose-escalation, U.S. Phase IIa trial of once-weekly subcutaneous PB1046 over 4 weeks. The first part will test PB1046 in about 28 patients with stab...